AR099936A1 - Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados - Google Patents
Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionadosInfo
- Publication number
- AR099936A1 AR099936A1 ARP150100989A ARP150100989A AR099936A1 AR 099936 A1 AR099936 A1 AR 099936A1 AR P150100989 A ARP150100989 A AR P150100989A AR P150100989 A ARP150100989 A AR P150100989A AR 099936 A1 AR099936 A1 AR 099936A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- groups
- substituted
- cycloalkyl
- Prior art date
Links
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title abstract 2
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- -1 OR8 Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos heterocíclicos condensados sustituidos. Los compuestos heterocíclicos condensados sustituidos son moduladores de GPR119 y son útiles para la prevención y/o el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados. Además el uso de compuestos heterocíclicos condensados sustituidos como ingredientes activos en productos farmacéuticos, y a composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto de la fórmula (1) en la que A es N o C; B es CO, N o CH; E es N o C; G es N o CR³⁰; en donde al menos uno de los grupos A, B, E o G es N; R³⁰ es H o (CR¹¹R¹²)ₙ-R³²; R¹¹, R¹² son independientemente uno de otro H o alquilo C₁₋₆; n es 0, 1, 2 ó 3; R³² es alquilo C₁₋₆, cicloalquilo C₃₋₈, COOR¹³, CONR¹⁴R¹⁵, SO₂R¹⁶ o OH; R¹³ es H o alquilo C₁₋₆; R¹⁴, R¹⁵ son independientemente uno de otro H, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con OR¹⁷, o cicloalquilo C₃₋₆; o R¹⁴ y R¹⁵ forman junto con el átomo de N al que están unidos, un heterociclo de 4, 5 ó 6 miembros, que opcionalmente contiene un heteroátomo adicional seleccionado de la lista de O, S y NR¹⁸; en donde el heterociclo de 4, 5 ó 6 miembros puede estar opcionalmente sustituido con 1 a 3 grupos seleccionados de la lista de alquilo C₁₋₄ y OR¹⁷; R¹⁶ es alquilo C₁₋₆; R¹⁷ es H o alquilo C₁₋₆; R¹⁸ es H o alquilo C₁₋₆; R¹ᵃ, R¹ᵇ, R¹ᶜ son independientemente uno de otro H, F, Cl, Br, alquilo C₁₋₆ o CN; R²ᵃ, R²ᵇ, R²ᶜ son independientemente uno de otro H, F, Cl, Br, alquilo C₁₋₆ o CN; Y es N o CH; Z es un enlace, O, CR⁵R⁵, NR⁶, C=O, S, SO o SO₂; R⁵, R⁵, R⁶ son independientemente uno de otro H o alquilo C₁₋₄; R³ es un enlace o (CR⁷R⁷)ₚ; p es 0, 1, 2, 3 ó 4; R⁷, R⁷ son independientemente uno de otro H o alquilo C₁₋₆; R⁴ es alquilo C₁₋₆, OR⁸, cicloalquilo C₃₋₈, bicicloalquilo C₅₋₈, heterociclo de 4, 5 ó 6 miembros, fenilo o anillo heteroarilo de 5 ó 6 miembros; en donde los grupos cicloalquilo C₃₋₈, bicicloalquilo C₅₋₈, heterociclo de 4, 5 ó 6 miembros, fenilo, anillo heteroarilo de 5 ó 6 miembros pueden estar opcionalmente sustituidos con 1 a 3 grupos seleccionados de alquilo C₁₋₄, alcanoilo C₁₋₄, hidroxi, hidroxi-alquilo C₁₋₄, alquiloxi C₁₋₃-alquilo C₁₋₄, oxo, F o Cl; R⁸ es H, alquilo C₁₋₆, hidroxi-alquilo C₁₋₄ o alquiloxi C₁₋₃-alquilo C₁₋₄; en donde en cada aparición los átomos de hidrógeno de los grupos alquilo pueden estar parcial o totalmente reemplazados por átomos de flúor; en cualquiera de sus formas estereoisómeras, o una mezcla de formas estereoisómeras en cualquier proporción, o una de sus sales fisiológicamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305494 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099936A1 true AR099936A1 (es) | 2016-08-31 |
Family
ID=50513859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100989A AR099936A1 (es) | 2014-04-04 | 2015-04-01 | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9758520B2 (es) |
| EP (1) | EP3126336B1 (es) |
| JP (1) | JP2017509679A (es) |
| KR (1) | KR20160132885A (es) |
| CN (1) | CN106164073A (es) |
| AR (1) | AR099936A1 (es) |
| AU (1) | AU2015239021A1 (es) |
| CA (1) | CA2942753A1 (es) |
| CL (1) | CL2016002497A1 (es) |
| CR (1) | CR20160460A (es) |
| DO (1) | DOP2016000212A (es) |
| EA (1) | EA030410B1 (es) |
| EC (1) | ECSP16078779A (es) |
| IL (1) | IL248129A0 (es) |
| MA (1) | MA39346B1 (es) |
| MX (1) | MX2016013033A (es) |
| PE (1) | PE20161378A1 (es) |
| PH (1) | PH12016501619A1 (es) |
| SG (1) | SG11201606758SA (es) |
| TW (1) | TW201625605A (es) |
| WO (1) | WO2015150564A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3126354T3 (pl) | 2014-04-04 | 2020-06-15 | H. Lundbeck A/S | Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1 |
| TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| WO2018153849A1 (en) | 2017-02-21 | 2018-08-30 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| CN110548147B (zh) * | 2018-05-31 | 2022-01-14 | 华领医药技术（上海）有限公司 | 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途 |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| MX2021014410A (es) * | 2019-05-31 | 2022-03-17 | Avolynt | Composiciones y métodos para tratar la enfermedad metabólica. |
| ES3042146T3 (en) * | 2019-11-05 | 2025-11-18 | Resverlogix Corp | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CN115667277A (zh) | 2020-02-28 | 2023-01-31 | 卡尔优普公司 | Gpr40激动剂 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004110994A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Products Inc. | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams |
| EP2029579B1 (en) * | 2006-04-21 | 2014-12-31 | Eli Lilly And Company | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| KR20130113948A (ko) * | 2010-05-17 | 2013-10-16 | 어레이 바이오파마 인크. | Gpr119 조절제로서의 피페리디닐-치환된 락탐류 |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| RU2013117403A (ru) | 2010-09-17 | 2014-10-27 | Эррэй Биофарма Инк. | Пиперидинил-замещенные лактамы как модуляторы gpr119 |
| CA2853784A1 (en) | 2011-11-11 | 2013-05-16 | Glaxosmithkline Llc | Treatment of blood lipid abnormalities and other conditions |
| TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
-
2015
- 2015-04-01 TW TW104110619A patent/TW201625605A/zh unknown
- 2015-04-01 AR ARP150100989A patent/AR099936A1/es unknown
- 2015-04-02 PE PE2016001909A patent/PE20161378A1/es not_active Application Discontinuation
- 2015-04-02 CN CN201580017438.3A patent/CN106164073A/zh active Pending
- 2015-04-02 WO PCT/EP2015/057414 patent/WO2015150564A1/en not_active Ceased
- 2015-04-02 EA EA201692008A patent/EA030410B1/ru not_active IP Right Cessation
- 2015-04-02 EP EP15713528.6A patent/EP3126336B1/en active Active
- 2015-04-02 KR KR1020167026911A patent/KR20160132885A/ko not_active Withdrawn
- 2015-04-02 CR CR20160460A patent/CR20160460A/es unknown
- 2015-04-02 MA MA39346A patent/MA39346B1/fr unknown
- 2015-04-02 JP JP2016560725A patent/JP2017509679A/ja not_active Abandoned
- 2015-04-02 SG SG11201606758SA patent/SG11201606758SA/en unknown
- 2015-04-02 MX MX2016013033A patent/MX2016013033A/es unknown
- 2015-04-02 CA CA2942753A patent/CA2942753A1/en not_active Abandoned
- 2015-04-02 AU AU2015239021A patent/AU2015239021A1/en not_active Abandoned
-
2016
- 2016-08-15 DO DO2016000212A patent/DOP2016000212A/es unknown
- 2016-08-15 PH PH12016501619A patent/PH12016501619A1/en unknown
- 2016-09-29 IL IL248129A patent/IL248129A0/en unknown
- 2016-09-30 CL CL2016002497A patent/CL2016002497A1/es unknown
- 2016-10-03 US US15/284,213 patent/US9758520B2/en not_active Expired - Fee Related
- 2016-10-04 EC ECIEPI201678779A patent/ECSP16078779A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2016000212A (es) | 2016-11-15 |
| US9758520B2 (en) | 2017-09-12 |
| CR20160460A (es) | 2017-02-21 |
| TW201625605A (zh) | 2016-07-16 |
| CL2016002497A1 (es) | 2017-03-31 |
| AU2015239021A1 (en) | 2016-10-13 |
| CN106164073A (zh) | 2016-11-23 |
| MX2016013033A (es) | 2017-01-09 |
| PE20161378A1 (es) | 2016-12-26 |
| KR20160132885A (ko) | 2016-11-21 |
| MA39346B1 (fr) | 2019-03-29 |
| US20170022198A1 (en) | 2017-01-26 |
| EA030410B1 (ru) | 2018-07-31 |
| EP3126336B1 (en) | 2018-12-05 |
| EP3126336A1 (en) | 2017-02-08 |
| CA2942753A1 (en) | 2015-10-08 |
| WO2015150564A1 (en) | 2015-10-08 |
| ECSP16078779A (es) | 2017-02-24 |
| MA39346A1 (fr) | 2017-09-29 |
| PH12016501619A1 (en) | 2017-02-06 |
| JP2017509679A (ja) | 2017-04-06 |
| SG11201606758SA (en) | 2016-09-29 |
| IL248129A0 (en) | 2016-11-30 |
| EA201692008A1 (ru) | 2017-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099936A1 (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| AR099937A1 (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2020000261A (es) | Nuevos compuestos. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2018002326A (es) | Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5. | |
| AR103574A1 (es) | Compuestos tricíclicos y usos de lo mismos en medicina | |
| CL2016000060A1 (es) | Derivados piperidinil indol y su uso como inhibidores factor de complemento b. | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| MX2016010848A (es) | Ciclopentanos 1,2-sustituidos como antagonistas del receptor de la orexina. | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| AR094550A1 (es) | Inhibidores de btk | |
| PE20161323A1 (es) | Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |